Drug Delivery to the Lungs 2026
Connect with our team and discuss your formulation challenges, development objectives, and opportunities for innovation in inhalation drug delivery.

Advancing Dry Powder Inhalation Performance
Join Roquette at Drug Delivery to the Lungs (DDL) 2026, one of the leading scientific conferences focused on pulmonary and nasal drug delivery.
Discover how our inhalation solutions portfolio, including Qualicaps™ inhalation capsules and PEARLITOL® carrier technologies, can help address dry powder inhalation challenges and support reliable product performance.
As inhalation therapies continue to advance, formulators are challenged to balance performance, manufacturability and patient needs. At DDL 2026, we will showcase how integrated capsule and excipient solutions can support the development of reliable dry powder inhaler (DPI) formulations.
Featured solutions include QUALI-V®-I hydroxypropyl methylcellulose (HPMC) capsules, QUALI-G™-I gelatin capsules, and PEARLITOL® 200 INH mannitol, bringing together capsule technologies, carrier expertise, and formulation support for inhalation applications.
Visit Booth 178 to connect with our team and discuss your formulation challenges, development objectives, and opportunities for innovation in inhalation drug delivery.
We look forward to meeting the inhalation science community in Edinburgh and exploring the future of dry powder inhalation together.
Meet Us at Booth 178
To schedule a meeting during DDL 2026, contact your Roquette representative.